DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostate Cancer

Intervention: valproic acid (Drug); standard follow-up care (Procedure)

Phase: Phase 2

Status: Recruiting

Sponsored by: Sidney Kimmel Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
Ronald Rodriguez, MD, PhD, Principal Investigator, Affiliation: Sidney Kimmel Comprehensive Cancer Center


RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well valproic acid works in treating patients with progressive, non-metastatic prostate cancer.

Clinical Details

Official title: Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer

Study design: Allocation: Randomized, Primary Purpose: Treatment

Primary outcome: Percentage of patients exhibiting observed or predicted prostate-specific antigen (PSA) doubling time > 10 months after initiation of the study

Secondary outcome:

Duration of PSA response

Percentage of patients who achieve a complete response

Percentage of patients who achieve a partial response

Self-perceived functionality, psychosocial well-being, and quality of life

Detailed description: OBJECTIVES: Primary

- Assess whether treatment with valproic acid (a type I histone deacetylase inhibitor)

can alter the kinetics of prostate-specific antigen (PSA) progression in patients with non-metastatic prostate cancer and biochemical progression. Secondary

- Determine the duration of PSA response.

- Assess the percentage of patients who achieve a complete response.

- Assess the percentage of patients who achieve a partial response.

- Assess the quality of life of these patients.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 arms.

- Arm I (observation): Patients undergo observation according to standard of care.

- Arm II (valproic acid): Patients receive oral valproic acid twice daily for up to 1

year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.


Minimum age: 18 Years. Maximum age: 85 Years. Gender(s): Male.



- Histologically confirmed prostate cancer

- Asymptomatic, non-metastatic disease

- Biochemical progression after definitive local therapy (radical prostatectomy)

- Most recent prostate-specific antigen (PSA) level ≥ 1. 0 ng/mL AND rising over

the prior value

- No clinical or radiological evidence of local progression

- PSA doubling time (DT) < 10 months after local therapy (in patients who have not

received prior hormone therapy)

- At least three PSA values (each at least 4 weeks apart) are required to

calculate the PSA-DT

- No clinical or radiological evidence of metastatic disease, including bone metastasis


- ECOG performance status 0-2

- Life expectancy > 3 months

- Total bilirubin normal

- AST/ALT < 2. 5 times upper limit of normal

- Creatinine ≤ 2. 5 mg/dL

- Platelet count > 125,000/mm^3

- PT and aPTT ≤ 1. 3 times above the standard reference

- Albumin ≥ 3. 5 g/dL

- Geographically accessible and willing to participate in all stages of study treatment

- No active second malignancy

- No known HIV positivity

- No active, uncontrolled infection (e. g., hepatitis A, B, or C infection)

- No history of allergic reactions attributed to compounds of similar chemical or

biological composition to valproic acid

- No debilitating medical or psychiatric illness that would preclude giving informed

consent or receiving optimal study treatment and follow-up

- No history of hepatic disease or significant hepatic dysfunction

- No history of pancreatitis

- No history of seizure disorder or clinically treated bipolar disorder


- More than 6 months since prior hormone therapy

- No prior valproic acid

- At least 2 weeks since prior drugs specifically known to interact with valproic acid

including, but are not limited to, aspirin, felbamate, rifampin, amitriptyline/nortriptyline, carbamazepine, clonazepam, diazepam, ethosuximide, lamotrigine, phenobarbital, primidone, phenytoin, tolbutamide, warfarin, or zidovudine

- No concurrent systemic chemotherapy for prostate cancer

- No other concurrent investigational drugs

Locations and Contacts

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-2410, United States; Recruiting
Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce, Phone: 410-955-8804, Email: jhcccro@jhmi.edu
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: May 2008
Last updated: February 18, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017